In a paper released in the New England Journal of Medicine, a group of professionals at Beth Israel Deaconess Medical Center (BIDMC) compared immune responses induced by the 3 vaccines over an eight-month follow-up period. The investigators evaluated the 61 individuals levels of different antibodies, T cells, and other immune items at 2 to four weeks following total immunization– the time of peak immunity– to 8 months after vaccination. Thirty-one participants received the BNT162b2 vaccine, 22 received the mRNA-1273 vaccine and 8 received the Ad26.COV2.S vaccine..
” The mRNA vaccines were defined by high peak antibody actions that decreased dramatically by month six and declined further by month eight,” stated matching author Dan H. Barouch, MD, PhD, director of the Center for Virology and Vaccine Research at BIDMC, who assisted establish the Ad26 platform in collaboration with Johnson & & Johnson. “The single-shot Ad26 vaccine caused lower preliminary antibody responses, however these responses were typically stable in time with minimal to no proof of decrease.”.
The group likewise discovered that mRNA-1273 elicited antibody actions which were typically higher and more durable than BNT162b2. All 3 vaccines showed broad cross-reactivity to variants of SARS-CoV-2, the infection that triggers COVID-19. The findings have important ramifications for understanding how vaccine immunity may subside with time; however, the accurate immune responses essential to confer defense against SARS-CoV-2 has actually not yet been figured out, the researchers mention..
” Even though neutralizing antibody levels decline, steady T cell reactions and non-neutralizing antibody functions at 8 months may explain how the vaccines continue to offer robust protection against serious COVID-19,” said lead author Ai-ris Y. Collier, MD, a maternal-fetal medicine specialist at BIDMC. ” Getting immunized ( even during pregnancy) is still the finest tool we need to end the COVID-19 pandemic.”.
Reference: “Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines” by Ai-ris Y. Collier, M.D.; Jingyou Yu, Ph.D.; Katherine McMahan, M.S.; Jinyan Liu, Ph.D.; Abishek Chandrashekar, M.S.; Jenny S. Maron, B.S.; Caroline Atyeo, M.S.; David R. Martinez, Ph.D.; Jessica L. Ansel, N.P.; Ricardo Aguayo, B.S.; Marjorie Rowe, B.S.; Catherine Jacob-Dolan, B.S.; Daniel Sellers, B.S.; Julia Barrett, B.S.; Kunza Ahmad, M.S.; Tochi Anioke, B.S.; Haley VanWyk, B.S.; Sarah Gardner, B.S.; Olivia Powers, B.S.; Esther A. Bondzie, B.A.; Huahua Wan, M.S.; Ralph S. Baric, Ph.D.; Galit Alter, Ph.D.; Michele R. Hacker, Sc.D. and Dan H. Barouch, M.D., Ph.D., 15 October 2021, New England Journal of Medicine.DOI: 10.1056/ NEJMc2115596.
Co-authors included Jingyou Yu, PhD, Katherine McMahan, MS, Jinyan Liu, PhD, Abishek Chandrashekar, MS, Jessica L. Ansel, NP, Marjorie Rowe, BS, Ricardo Aguayo, BS, Catherine Jacob-Dolan, BS, Daniel Sellers, BS, Julia Barrett, BS, Kunza Ahmad, MS, Tochi Anioke, BS, Haley VanWyk, BS, Sarah Gardner, BS, Olivia Powers, BS, Esther A. Bondzie, BA, Huahua Wan, MS, and Michele R. Hacker, ScD of BIDMC; Jenny S. Maron, BS, Caroline Atyeo, MS and Galit Alter, PhD, of Ragon Institute of MGH, MIT and Harvard; and David R. Martinez, PhD, and Ralph S. Baric, PhD of University of North Carolina at Chapel Hill..
The authors acknowledge Janssen Vaccines && Prevention, the National Institutes of Health (grant CA26047), the Massachusetts Consortium for Pathogen Readiness, the Ragon Institute and the Musk Foundation. The authors likewise acknowledge the Reproductive Scientist Development Program for the Eunice Kennedy Shriver National Institute of Child Health & & Human Development and Burroughs Wellcome Fund (grant HD000849), the Harvard Clinical and Translational Science Center ( grant TR0025410), and a Hannah H. Gray Fellowship from the Howard Hughes Medical Institute and a Burroughs Wellcome Fund Postdoctoral Enrichment Award..
Barouch is a co-inventor on provisional vaccine patents (63/121, 482; 63/133, 969; 63/135, 182). Please see the paper for a complete list of disclosures..
Strong antibody action to mRNA vaccines decreased over an eight-month follow-up duration; lower initial response to single-shot Ad26 vaccine stayed stable gradually, research programs.
Based upon the strength of scientific trial data showing the vaccines provided robust security against COVID-19, the U.S. Food & & Drug Administration gave emergency situation usage permission to the mRNA-based vaccines called BNT162b2 ( BioNTech, Pfizer) and mRNA-1273 ( Moderna) in December 2020, and to the Ad26.COV2.S ( Johnson & & Johnson ) single-shot vaccine in February 2021. To date, nearly 200 million Americans have received a COVID-19 vaccine, and as some method the 1 year anniversary of their immunization, concerns stay about the vaccines long-lasting efficacy..
In a paper released in the New England Journal of Medicine, a group of professionals at Beth Israel Deaconess Medical Center (BIDMC) compared immune responses induced by the 3 vaccines over an eight-month follow-up period. The investigators examined the 61 individuals levels of different antibodies, T cells, and other immune products at two to four weeks following complete immunization– the time of peak immunity– to 8 months after vaccination.
